| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Replimune Group Inc (NASDAQ: REPL)
REPL Technical Analysis
3
| As on 30th Jul 2025 REPL SHARE Price closed @ 7.55 and we RECOMMEND Sell for LONG-TERM with Stoploss of 9.60 & Sell for SHORT-TERM with Stoploss of 7.79 we also expect STOCK to react on Following IMPORTANT LEVELS. |
REPLSHARE Price
| Open | 6.42 | Change | Price | % |
| High | 8.07 | 1 Day | 3.80 | 101.33 |
| Low | 5.71 | 1 Week | -4.77 | -38.72 |
| Close | 7.55 | 1 Month | -2.28 | -23.19 |
| Volume | 201746091 | 1 Year | -0.21 | -2.71 |
| 52 Week High 14.93 | 52 Week Low 2.81 | ||||
NASDAQ USA Most Active Stocks
| HCTI | 0.03 | -40.00% |
| AMRS | 0.14 | 100.00% |
| REPL | 7.55 | 101.33% |
| SOFI | 21.87 | -2.37% |
| NVDA | 179.27 | 2.14% |
| OPEN | 2.07 | 0.98% |
| NCNA | 0.05 | 0.00% |
| LMDX | 0.02 | 0.00% |
| AKTS | 0.04 | 0.00% |
| ESSA | 635.00 | 1.60% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| REPL Daily Charts |
REPL Intraday Charts |
Whats New @ Bazaartrend |
REPL Free Analysis |
|
|
REPL Important Levels Intraday
| RESISTANCE | 12.10 |
| RESISTANCE | 10.64 |
| RESISTANCE | 9.74 |
| RESISTANCE | 8.84 |
| SUPPORT | 6.26 |
| SUPPORT | 5.36 |
| SUPPORT | 4.46 |
| SUPPORT | 3.00 |
REPL Forecast August 2025
| 4th UP Forecast | 12.56 |
| 3rd UP Forecast | 10.95 |
| 2nd UP Forecast | 9.96 |
| 1st UP Forecast | 8.97 |
| 1st DOWN Forecast | 6.13 |
| 2nd DOWN Forecast | 5.14 |
| 3rd DOWN Forecast | 4.15 |
| 4th DOWN Forecast | 2.54 |
REPL Weekly Forecast
| 4th UP Forecast | 10.44 |
| 3rd UP Forecast | 9.51 |
| 2nd UP Forecast | 8.94 |
| 1st UP Forecast | 8.37 |
| 1st DOWN Forecast | 6.73 |
| 2nd DOWN Forecast | 6.16 |
| 3rd DOWN Forecast | 5.59 |
| 4th DOWN Forecast | 4.66 |
REPL Forecast2025
| 4th UP Forecast | 35.14 |
| 3rd UP Forecast | 26.29 |
| 2nd UP Forecast | 20.82 |
| 1st UP Forecast | 15.35 |
| 1st DOWN Forecast | -0.25 |
| 2nd DOWN Forecast | -5.72 |
| 3rd DOWN Forecast | -11.19 |
| 4th DOWN Forecast | -20.04 |
Replimune Group Inc ( NASDAQ USA Symbol : REPL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
REPL Business Profile
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Address: 500 Unicorn Park Drive, Woburn, MA, United States, 01801
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service